Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 23394097)

1.
2.

The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.

Valenti L, Rametta R, Ruscica M, Dongiovanni P, Steffani L, Motta BM, Canavesi E, Fracanzani AL, Mozzi E, Roviaro G, Magni P, Fargion S.

BMC Gastroenterol. 2012 Aug 16;12:111.

3.

PNPLA3 I148M polymorphism and progressive liver disease.

Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L.

World J Gastroenterol. 2013 Nov 7;19(41):6969-78. doi: 10.3748/wjg.v19.i41.6969. Review.

4.

Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.

Schuppan D, Schattenberg JM.

J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:68-76. doi: 10.1111/jgh.12212. Review.

PMID:
23855299
5.

Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation.

Tilg H, Moschen A.

Curr Opin Clin Nutr Metab Care. 2010 Jul;13(4):391-6. doi: 10.1097/MCO.0b013e32833a87cc. Review.

PMID:
20473151
6.

Non-alcoholic fatty liver disease.

Smith BW, Adams LA.

Crit Rev Clin Lab Sci. 2011 May-Jun;48(3):97-113. doi: 10.3109/10408363.2011.596521. Review.

PMID:
21875310
7.

[Non-alcoholic fatty liver disease--new view].

Raszeja-Wyszomirska J, Lawniczak M, Marlicz W, Miezyńska-Kurtycz J, Milkiewicz P.

Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Review. Polish.

PMID:
18702346
8.

The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population.

Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, Huang JF, Chen SC, Li SS, Chuang WL.

Liver Int. 2011 Oct;31(9):1326-31. doi: 10.1111/j.1478-3231.2011.02526.x. Epub 2011 Apr 5.

PMID:
21745282
9.

I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.

Valenti L, Alisi A, Galmozzi E, Bartuli A, Del Menico B, Alterio A, Dongiovanni P, Fargion S, Nobili V.

Hepatology. 2010 Oct;52(4):1274-80. doi: 10.1002/hep.23823.

PMID:
20648474
10.

Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).

Podrini C, Borghesan M, Greco A, Pazienza V, Mazzoccoli G, Vinciguerra M.

Curr Pharm Des. 2013;19(15):2737-46. Review.

PMID:
23092327
11.

Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.

Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F; Takeshi Okanoue, Japan Study Group of Nonalcoholic Fatty Liver Disease.

PLoS One. 2012;7(6):e38322. doi: 10.1371/journal.pone.0038322. Epub 2012 Jun 14.

12.
13.

Nonalcoholic fatty liver disease.

Krawczyk M, Bonfrate L, Portincasa P.

Best Pract Res Clin Gastroenterol. 2010 Oct;24(5):695-708. doi: 10.1016/j.bpg.2010.08.005. Review.

PMID:
20955971
14.

From the metabolic syndrome to NAFLD or vice versa?

Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G.

Dig Liver Dis. 2010 May;42(5):320-30. doi: 10.1016/j.dld.2010.01.016. Epub 2010 Mar 6. Review.

PMID:
20207596
15.

Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.

Stein LL, Dong MH, Loomba R.

Adv Ther. 2009 Oct;26(10):893-907. doi: 10.1007/s12325-009-0072-z. Epub 2009 Nov 16. Review.

PMID:
19921118
16.

Etiopathogenesis of nonalcoholic steatohepatitis.

Chitturi S, Farrell GC.

Semin Liver Dis. 2001;21(1):27-41. Review.

PMID:
11296694
17.

[Nonalcoholic steatohepatitis: pathogenesis and treatment].

Park SH.

Korean J Hepatol. 2008 Mar;14(1):12-27. doi: 10.3350/kjhep.2008.14.1.12. Review. Korean.

18.

Recent concepts in non-alcoholic fatty liver disease.

Adams LA, Angulo P.

Diabet Med. 2005 Sep;22(9):1129-33. Review.

PMID:
16108837
19.

Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.

Younossi ZM.

Aliment Pharmacol Ther. 2008 Jul;28(1):2-12. doi: 10.1111/j.1365-2036.2008.03710.x. Epub 2008 Apr 11. Review.

PMID:
18410557
20.

Update on the treatments of non-alcoholic fatty liver disease (NAFLD).

Quercioli A, Montecucco F, Mach F.

Cardiovasc Hematol Disord Drug Targets. 2009 Dec;9(4):261-70. Review.

PMID:
19751186
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk